摘要
目的探讨Kv7通道开放剂氟吡汀、瑞替加滨与阿司匹林联合应用的镇痛作用,为临床联合用药提供科学依据。方法实验分为对照组、阿司匹林组、氟吡汀组、瑞替加滨组、阿司匹林+瑞替加滨组、阿司匹林+氟吡汀组。采用冰醋酸致扭体法、热板法评价各组药物的镇痛效果。结果扭体法中,与阿司匹林组相比,阿司匹林+氟吡汀组的扭体次数明显减少(P<0.01),阿司匹林+瑞替加滨组的扭体反应潜伏期明显延长(P<0.01),扭体次数明显减少(P<0.01);热板法中,与阿司匹林组相比,阿司匹林+氟吡汀组与阿司匹林+瑞替加滨组的舔后足潜伏期延长率均增加,其中,阿司匹林+瑞替加滨组在30 min、60 min时的舔后足潜伏期延长率与阿司匹林组相比有明显差异(P<0.05)。结论Kv7通道开放剂氟吡汀、瑞替加滨可以增强阿司匹林的镇痛作用。
Aim To provide scientific evidence for clinical drug combination by exploring the analgesic effect of aspirin combined with Kv7 channel openers,retigabine and flupirtine.Methods The mice were randomly divided into control group,aspirin group,flupirtine group,retigabine group,aspirin+flupirtine group and aspirin+retigabine group.To assess the antinociceptive effects of each group,the acetic acid-induced abdominal constriction test and the hot-plate test were used.Results In the acetic acid-induced abdominal constriction test,compared to aspirin group,the amount of abdominal constriction in aspirin+flupirtine group was significantly reduced(P<0.01).The latent period of abdominal constriction in aspirin+retigabine group was significantly prolonged(P<0.01)and the number of abdominal constriction was significantly reduced(P<0.01).In the hot-plate test,compared to aspirin group,the increment percentage of latent period in aspirin+flupirtine group and aspirin+retigabine group showed an increased trend.Among them,the increment percentage of latent period 30 and 60 minutes after injections in aspirin+retigabine group had a significant difference from that in aspirin group(P<0.05).Conclusion Kv7 channel openers,retigabine and flupirtine,can enhance the analgesic effect of aspirin.
作者
张佳瑜
徐晨悦
赵伊珂
周彦宏
金鑫
张国红
赵志英
ZHANG Jia-yu;XU Chen-yue;ZHAO Yi-ke;ZHOU Yan-hong;JIN Xin;ZHANG Guo-hong;ZHAO Zhi-ying(the Second Clinical Medical School,School of Basic Medical,Hebei Medical University,Shijiazhuang 050017,China;Experiment Center of Clinical College,School of Basic Medical,Hebei Medical University,Shijiazhuang 050017,China;Dept of Pharmacology,School of Basic Medical,Hebei Medical University,Shijiazhuang 050017,China)
出处
《中国药理学通报》
CAS
CSCD
北大核心
2020年第2期268-271,共4页
Chinese Pharmacological Bulletin
基金
国家自然科学基金青年基金项目(No 30900267)
教育部高等学校博士点专项科研基金(No 20091323120006)
河北医科大学科研发展基金(No kyfz024)
河北省科技计划项目(No 132777199)。